Form D · Biotechnology
Trubion Pharmaceuticals, Inc
Seattle, WA · CIK 0001298521
Offering snapshot reported Sep 4, 2009 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $10M Reported outside-investor minimum
- First sale
- Sep 1, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 4, 2009 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-67751
Source: Form D, filed Sep 4, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lee R. Brettman | Director |
| Michelle Burris | Executive |
| Kathleen M. Deeley | Executive |
| Steven Gillis | Director |
| Patrick Heron | Director |
| Anders D. Hove | Director |
| David A. Mann | Director |
| Kendall Mohler | Executive |
| Samuel R. Saks | Director |
| David Schnell | Director |
| Scott Stromatt | Executive |
| Peter Thompson | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2401 4 Th Avenue Suite 1050
Seattle, WA, 98121
Seattle, WA, 98121